Notice of Refund | Nov 22, 2017 | PAPER | BOARD |
Petitioner's Request for Refund of Post-Institution Fee | Nov 17, 2017 | PAPER | PETITIONER |
Trial Instituted Document | Oct 12, 2017 | PAPER | BOARD |
Ex. 2001 Chronic Lymphocyte Leukemia | Jul 18, 2017 | EXHIBIT | PATENT OWNER |
Ex. 2009 Taber's Medical Dictionary, Edition 18 (1997) | Jul 18, 2017 | EXHIBIT | PATENT OWNER |
Ex. 2011 Fludarabine and Acute Tumor Lysis in Chronic Lymphocytic Leukemia | Jul 18, 2017 | EXHIBIT | PATENT OWNER |
Ex. 2012 Declaration of Sharon Song | Jul 18, 2017 | EXHIBIT | PATENT OWNER |
Patent Owner's Exhibit List | Jul 18, 2017 | PAPER | PATENT OWNER |
Patent Owner Preliminary Response | Jul 18, 2017 | PAPER | PATENT OWNER |
Ex. 2002 Proposals for the Classification of Chronic (Mature) B and T Lymphoid Leukaemias | Jul 18, 2017 | EXHIBIT | PATENT OWNER |
Ex. 2003 Chronic Lymphocyte Leukemia | Jul 18, 2017 | EXHIBIT | PATENT OWNER |
Ex. 2004 Amendment and Reply to Office Action | Jul 18, 2017 | EXHIBIT | PATENT OWNER |
Ex. 2005 Request for Continued Examination | Jul 18, 2017 | EXHIBIT | PATENT OWNER |
Ex. 2006 Fatal Acute Tumor Lysis Syndrome With Metastatic Breast Carcinoma | Jul 18, 2017 | EXHIBIT | PATENT OWNER |
Ex. 2007 Clinical Development Success Rates 2006-2005 | Jul 18, 2017 | EXHIBIT | PATENT OWNER |
Ex. 2008 Definition of "Leukemia" NCI Dictionary of Cancer Terms | Jul 18, 2017 | EXHIBIT | PATENT OWNER |
Ex. 2010 Non-Institution Decision, Boehringer Ingelheim International GmbH v. Biogen Idec, Inc. | Jul 18, 2017 | EXHIBIT | PATENT OWNER |
Patent Owner's Updated Mandatory Notice | Jul 14, 2017 | PAPER | PATENT OWNER |
Power of Attorney | Apr 21, 2017 | PAPER | PATENT OWNER |
Mandatory Notice | Apr 21, 2017 | PAPER | PATENT OWNER |
Notice of Accord Filing Date | Apr 18, 2017 | PAPER | BOARD |
Authorization to Charge Additional Fees | Apr 17, 2017 | PAPER | PETITIONER |
U.S. Patent No. 7,682,612 | Mar 31, 2017 | EXHIBIT | PETITIONER |
U.S. Provisional Application No. 60/107,658 | Mar 31, 2017 | EXHIBIT | PETITIONER |
Petitioner's Power of Attorney | Mar 31, 2017 | PAPER | PETITIONER |
Part 1 - Excerpts of File History for U.S. Patent No. 7,682,612 | Mar 31, 2017 | EXHIBIT | PETITIONER |
Archived website for Leukemia Insights Newsletter, 3(1) (Last updated July 2, 1998) | Mar 31, 2017 | EXHIBIT | PETITIONER |
Part 2 - Excerpts of File History for U.S. Patent No. 7,682,612 | Mar 31, 2017 | EXHIBIT | PETITIONER |
Declaration of Michael Andreeff M.D. | Mar 31, 2017 | EXHIBIT | PETITIONER |
Public Hearing Transcript, Biological Response Modifiers Advisory Committee, Center for Biological Evaluation and Research, Food and Drug Administration, nineteenth meeting (July 25, 1997) | Mar 31, 2017 | EXHIBIT | PETITIONER |
Batata, et al., Relationship between Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Comparative Study of Membrane Phenotypes in 270 Cases, Cancer 70(3):625-632 (1992) | Mar 31, 2017 | EXHIBIT | PETITIONER |
Maloney et al., IDEC-C2B8: Results of a Phase I Multiple-Dose Trial in Patents With Relapsed Non-Hodgkin's Lymphoma, J. Clin. Oncol. (Oct. 1997) 15(10):3266-3274 | Mar 31, 2017 | EXHIBIT | PETITIONER |
Link et al., Phase II Pilot Study of the Safety and Efficacy of Rituximab in Combination with CHOP Chemotherapy in Patients with Previously Untreated Intermediate- or High-Grade NHL, Program/Proceedings Am Soc Clin Oncol, 17:3a (Abstract *7) (1998) | Mar 31, 2017 | EXHIBIT | PETITIONER |
The Non-Hodgkin's Lymphoma Pathologic Classification Project, National Cancer Institute Sponsored Study of Classification of Non-Hodgkin's Lymphomas: Summary and Description etc., Cancer 49(10):2112-2135 (May 15, 1982) | Mar 31, 2017 | EXHIBIT | PETITIONER |
Harris et al., A Revised European-American Classification of Lymphoid Neoplasms: A Proposal From the International Lymphoma Study Group, Blood 84(5):1361-1392 (Sept. 1, 1994) | Mar 31, 2017 | EXHIBIT | PETITIONER |
Protocol for Phase I/II Study of IDEC-C2B8 (Rituximab) for Relapsed CLL (DM97-236) (dated December 10, 1997) | Mar 31, 2017 | EXHIBIT | PETITIONER |
Maloney et al., Phase I Clinical Trial Using Escalating Single-Dose infusion of Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8) in Patients with Recurrent B-Cell Lymphoma, Blood 84(8):2457-2466 (October 15, 1994) | Mar 31, 2017 | EXHIBIT | PETITIONER |
Byrd et al., Old and New Therapies in Chronic Lymphocytic Leukemia: Now Is the Time for a Reassessment of Therapeutic Goals, Semin. Oncol. (February 1998) 25(1):65-74 | Mar 31, 2017 | EXHIBIT | PETITIONER |
Czuczman et al., Chemoimmunotherapy of Low-Grade Lymphoma with the Anti-CD20 Antibody IDEC-C2B8 in Combination with CHOP Chemotherapy, Cancer Invest. 14:59-61 (Abstract 53) (1996) | Mar 31, 2017 | EXHIBIT | PETITIONER |
Harris et al., World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meeting-Airlie House, VA, Nov, 1997, J. Clin. Oncol. 17(12):3835-3849 (Dec. 1999) | Mar 31, 2017 | EXHIBIT | PETITIONER |
Anderson, Targeted Anti-Cancer Therapy Using Rituximab, a Chimaeric Anti-CD20 Antibody (IDEC C2B8) in the Treatment of Non-Hodgkin's B-Cell Lymphoma, Biochemical Society Transactions 25(2):705-708 (May 1997) | Mar 31, 2017 | EXHIBIT | PETITIONER |
Maloney et al., IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma, Blood 90(6):2188-2195 (Sept. 15, 1997) | Mar 31, 2017 | EXHIBIT | PETITIONER |
McLaughlin et al., Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program, J. Clin, Oncol. 16(8):2825-2833 (Aug. 1998) | Mar 31, 2017 | EXHIBIT | PETITIONER |
Hiddemann et al., Lymphoma Classification-The Gap Between Biology and Clinical Management Is Closing, Blood 88(11):4085-4089 (Dec. 1, 1996) | Mar 31, 2017 | EXHIBIT | PETITIONER |
Ford et al., Immunotherapeutic Approaches to Treatment of B-Cell Neoplasms: Focus on Unconjugated Antibodies, Highlights in Oncology Practice, 16(2):40-50 (1998) | Mar 31, 2017 | EXHIBIT | PETITIONER |
Hall et al., Mechanisms of Action of, and Modes of Resistance to, Alkylating Agents Used in the Treatment of Haematological Malignancies, Blood Reviews 163-173 (1992) | Mar 31, 2017 | EXHIBIT | PETITIONER |
Beigleiter et al., Chlorambucil in Chronic Lymphocytic Leukemia: Mechanism of Action, Leuk. Lymphoma 23:187-201 (1996) | Mar 31, 2017 | EXHIBIT | PETITIONER |
Keating et al., Long-Term Follow-Up of Patients with Chronic Lymphocytic Leukemia (CLL) Receiving Fludarabine Regimens as Initial Therapy, Blood 92(4):1165-1171 (Aug. 15, 1998) | Mar 31, 2017 | EXHIBIT | PETITIONER |
Johnson et al., Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia, Lancet 347:1432-1438 (May 5, 1996) | Mar 31, 2017 | EXHIBIT | PETITIONER |
Obrien et al., Results of the Fludarabine and Cyclophosphamide Combination Regimen in Chronic Lymphocytic Leukemia, J. Clin. Oncol. 19(5):1414-1420 (March 1, 2001) | Mar 31, 2017 | EXHIBIT | PETITIONER |
Koehl et al., Fludarabine and cyclophosphamide: Synergistic cytotoxicity associated with inhibition of interstrand cross-link removal, Proc. Am. Assn. Cancer Res. 38:2 (Abstract 10) (March 1997) | Mar 31, 2017 | EXHIBIT | PETITIONER |
The Non-Hodgkin's Lymphoma Classification Project, A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma, Blood 89:(11):3909-3918 (June 1, 1997) | Mar 31, 2017 | EXHIBIT | PETITIONER |
Cheson et al., National Cancer Institute-Sponsored Working Group Guidelines for Chronic Lymphocytic Leukemia: Revised Guidelines for Diagnosis and Treatment, Blood 87(12):4990-4997 (June 15, 1996) | Mar 31, 2017 | EXHIBIT | PETITIONER |
Genentech Press Release, March 3, 1995 | Mar 31, 2017 | EXHIBIT | PETITIONER |
Stashenko et al., Characterization of a Human B Lymphocyte-Specific Antigen, J. Immunol. 125(4):1678-1685 (October 1980) | Mar 31, 2017 | EXHIBIT | PETITIONER |
Anderson et al., Expression of Human B Cell-Associated Antigens on Leukemias and Lymphomas: A Model of Human B Cell Differentiation, Blood 63(6):1424-1433 (June 1984) | Mar 31, 2017 | EXHIBIT | PETITIONER |
Leget et al., Use of rituximab, the new FDA-approved antibody, Curr. Opin. Oncol. 10:548-551 (1998) | Mar 31, 2017 | EXHIBIT | PETITIONER |
OBrien et al., Fludarabine (FAMP) and Cyclophosphamide (CTX) Therapy in Chronic Lymphocytic Leukemia (CLL), Blood 88(10, Supp. 1):480 (Abstract 1910) (November 15, 1996) | Mar 31, 2017 | EXHIBIT | PETITIONER |
Grillo-Lopez, Rituximab: An Insider's Historical Perspective, Semin. Oncol. 27(6 Supp. 12):9-16 (December 2000) | Mar 31, 2017 | EXHIBIT | PETITIONER |
Declaration of David P. Schenkein M.D. - U.S. Patent Appl. No. 09/436,347 dated November 14, 2008 | Mar 31, 2017 | EXHIBIT | PETITIONER |
Declaration of David P. Schenkein M.D. - U.S. Pat. Appl. No. 09/436,347 dated May 5, 2009 | Mar 31, 2017 | EXHIBIT | PETITIONER |
Jensen et al., Rapid tumor lysis in a patient with B-Cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab), Ann. Hematol. 77:89-91 (1998) | Mar 31, 2017 | EXHIBIT | PETITIONER |
U.S. Patent Application No. 09/372,202 | Mar 31, 2017 | EXHIBIT | PETITIONER |
Almasri et al., Reduced Expressions of CD20 Antigen as a Characteristic Marker for Chronic Lymphcytic Leukemia, Am. J. Hematol. 40(4):259-263 (1992) | Mar 31, 2017 | EXHIBIT | PETITIONER |
Foon, Laboratory and Clinical Applications of Monoclonal Antibodies for Leukemias and Non-Hodgkin's Lymphoma, Curr. Probl. Cancer 63-128 (March/April 1989) | Mar 31, 2017 | EXHIBIT | PETITIONER |
Foon et al., Chapter 111: Lymphomas in Williams Hematology, Fifth Edition, 1076-1096 (Beutler, et al., eds. 1995) | Mar 31, 2017 | EXHIBIT | PETITIONER |
Piro et al., RITUXAN (rituximab, IDEC-C2B8): Interim analysis of a phase II study of once weekly times 8 dosing in patients with relapsed low-grade or follicular non-Hodgkin's lymphoma, Blood 90(10 Supp. 1):510a (Abstract 2272) (1997) | Mar 31, 2017 | EXHIBIT | PETITIONER |
Declarationof Dr. Steven Edward Coutre M.D. in opposition to European Patent No. EP-B1 1 616 572 dated February 3, 2014 | Mar 31, 2017 | EXHIBIT | PETITIONER |
FDA FOIA Response Letter (August 26, 2016) | Mar 31, 2017 | EXHIBIT | PETITIONER |
Kipps, Chapter 106: Chronic lymphocytic leukemia and related diseases in Williams Hematology, Fifth Edition, 1017-1039 (Beutler et al., eds, 1995) | Mar 31, 2017 | EXHIBIT | PETITIONER |
Demidem et al., Chimeric Anti-CD20 (IDEC-C2B8) Monoclonal Antibody Sensitizes a B Cell Lymphoma Cell Line to Cell Killing by Cytotoxic Drugs, Cancer Biother. Radiopharm. 12(3):177-186 (1997) | Mar 31, 2017 | EXHIBIT | PETITIONER |
Second Declaration of David Schenkein in opposition to European Patent No. EP-B1 1 616 572 dated June 5, 2013 | Mar 31, 2017 | EXHIBIT | PETITIONER |
Declaration of Dr. Michael Wenger M.D. in opposition to European Patent No. EP-B1 1 616 572 dated January 31, 2014 | Mar 31, 2017 | EXHIBIT | PETITIONER |
WO 94/11026 | Mar 31, 2017 | EXHIBIT | PETITIONER |
U.S. Patent No. 6,455,043 | Mar 31, 2017 | EXHIBIT | PETITIONER |
Nguyen et al., IDEC-C2B8 anti-CD20 phase II trial: results on bone marrow and peripheral blood tumor response in patients with low grade Non-Hodgkin's (NHL) lymphoma/lymphoproliferative disorders (LPD), Blood 90(10 Supp. 1):511a (Abs. 2277) (Nov. 15, 1997) | Mar 31, 2017 | EXHIBIT | PETITIONER |
Williams et al., Chapter 2: Examination of the Blood in Williams Hematology, Fifth Edition, 8-15 (Beutler et al., eds., 1995) | Mar 31, 2017 | EXHIBIT | PETITIONER |
Leukemia Insights Newsletter, 3(2) (Summer 1998) | Mar 31, 2017 | EXHIBIT | PETITIONER |
Czuczman et al., IDEC-C2B8 (Rituximab) Alone and in Combination with CHOP in the Treatment of Low-Grade B-Cell Lymphoma, Cancer Invest., 16 (Supp. 1):21-22 (Abstract 17) (1998) | Mar 31, 2017 | EXHIBIT | PETITIONER |
Czuczman et al., IDEC-C2B8 (Rituximab) Alone and in Combination with CHOP in the Treatment of Low-Grade B-Cell Lymphoma, Cancer Invest., 16 (Supp. 1):21-22 (Abstract 17) (1998) | Mar 31, 2017 | EXHIBIT | PETITIONER |
Seng et al., Indolent B-cell Non-Hodgkin's Lymphomas, Oncology, 1(12):1883-1897 (December 1997) | Mar 31, 2017 | EXHIBIT | PETITIONER |
Declaration of Christopher Butler, Internet Archive, dated December 20, 2016, authenticating Archived website for Leukemia Insights Newsletter, 3(2) (Last updated July 2, 1998) | Mar 31, 2017 | EXHIBIT | PETITIONER |
Petition for Inter Partes Review of U.S. Patent No. 7,682,612, (Single agent Claims) | Mar 31, 2017 | PAPER | PETITIONER |